(IN BRIEF) GSK has agreed to acquire RAPT Therapeutics in a transaction valued at approximately $2.2 billion, adding ozureprubart, a phase IIb long-acting anti-IgE antibody for food allergy prevention, to its Respiratory, Immunology & Inflammation pipeline. Designed to offer sustained … Read the full press release →
Posted in Business, Healthcare, Investment, Pharma & Biotech, Science, Technology, United Kingdom
Tagged anti IgE therapy, biopharmaceutical acquisition, Brian Wong, clinical-stage biotech, Food allergy, GSK, GSK Expands Food Allergy Portfolio with Acquisition of RAPT and Ozureprubart Asset, Healthcare Innovation, immunology, monoclonal antibody, ozureprubart, pediatric allergy, phase IIb trial, prestIgE study, RAPT Therapeutics, respiratory and inflammation pipeline, Tony Wood
(IN BRIEF) EQT Life Sciences has invested in U.S.-based Kinaset Therapeutics as part of a USD 103 million oversubscribed Series B financing. The funding will support the clinical advancement of frevecitinib, a novel inhaled pan-JAK inhibitor designed to treat a … Read the full press release →
Posted in Business, Financial, Government, Healthcare, Industrial, Investment, Management, Pharma & Biotech, Science, Sweden, Technology
Tagged asthma treatment, biopharmaceuticals, clinical-stage biotech, Daniela Begolo, EQT Life Sciences, EQT Life Sciences Backs Kinaset Therapeutics in USD 103m Series B Financing, Forge Life Science Partners, frevecitinib, inhaled therapeutics, Kinaset Therapeutics, pan-JAK inhibitor, RA Capital Management, respiratory diseases, Series B financing
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?
Load more...
